Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.

Published

Journal Article (Review)

The induction of donor-specific tolerance to transplanted cells and organs, while preserving immune function as a whole, remains a highly sought after and elusive strategy for overcoming transplant rejection. Tolerance necessitates modulating a diverse array of cell types that recognize and respond to alloantigens, including antigen presenting cells and T lymphocytes. Nanotherapeutic strategies that employ cellular and biomaterial engineering represent an emerging technology geared towards the goal of inducing transplant tolerance. Nanocarriers offer a platform for delivering antigens of interest to specific cell types in order to achieve tolerogenic antigen presentation. Furthermore, the technologies also provide an opportunity for local immunomodulation at the graft site. Nanocarriers delivering a combination of antigens and immunomodulating agents, such as rapamycin, provide a unique technology platform with the potential to enhance outcomes for the induction of transplant tolerance.

Full Text

Duke Authors

Cited Authors

  • Hlavaty, KA; Luo, X; Shea, LD; Miller, SD

Published Date

  • September 2015

Published In

Volume / Issue

  • 160 / 1

Start / End Page

  • 14 - 23

PubMed ID

  • 25805659

Pubmed Central ID

  • 25805659

Electronic International Standard Serial Number (EISSN)

  • 1521-7035

International Standard Serial Number (ISSN)

  • 1521-6616

Digital Object Identifier (DOI)

  • 10.1016/j.clim.2015.03.013

Language

  • eng